[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA04004170A - Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9. - Google Patents

Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.

Info

Publication number
MXPA04004170A
MXPA04004170A MXPA04004170A MXPA04004170A MXPA04004170A MX PA04004170 A MXPA04004170 A MX PA04004170A MX PA04004170 A MXPA04004170 A MX PA04004170A MX PA04004170 A MXPA04004170 A MX PA04004170A MX PA04004170 A MXPA04004170 A MX PA04004170A
Authority
MX
Mexico
Prior art keywords
diabetes
type
insulin resistance
treatment
resistance syndrome
Prior art date
Application number
MXPA04004170A
Other languages
English (en)
Inventor
David Albert Fryburg
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA04004170A publication Critical patent/MXPA04004170A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invencion se dirige a un procedimiento para tratar el sindrome de resistencia a la insulina (IRS), hipertension y/o diabetes de tipo 2 en un mamifero, que comprende administrar al citado mamifero in inhibidor de CMPc PDE9 o una composicion farmaceuticamente aceptable del mismo; esta invencion se dirige tambien a procedimientos tales en los que se utiliza el citado inhibidor de CMPC PDE9 en combinacion con otros agentes para tratar el IRS, hipertension y/o diabetes de tipo 2.
MXPA04004170A 2001-11-02 2002-09-12 Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9. MXPA04004170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33698101P 2001-11-02 2001-11-02
PCT/IB2002/003754 WO2003037432A1 (en) 2001-11-02 2002-09-12 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors

Publications (1)

Publication Number Publication Date
MXPA04004170A true MXPA04004170A (es) 2004-09-06

Family

ID=23318571

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004170A MXPA04004170A (es) 2001-11-02 2002-09-12 Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.

Country Status (13)

Country Link
US (2) US6967204B2 (es)
EP (1) EP1444009A1 (es)
JP (1) JP2005508978A (es)
KR (1) KR20040053210A (es)
CN (1) CN1575191A (es)
BR (1) BR0213817A (es)
CA (1) CA2465632A1 (es)
HU (1) HUP0401998A2 (es)
IL (1) IL161155A0 (es)
MX (1) MXPA04004170A (es)
PL (1) PL370599A1 (es)
WO (1) WO2003037432A1 (es)
ZA (1) ZA200402173B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
US20030195205A1 (en) * 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
IL161155A0 (en) * 2001-11-02 2004-08-31 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
CA2468156A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Azolopyrimidinone compounds and their use
ES2280596T3 (es) * 2001-12-29 2007-09-16 Novo Nordisk A/S Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
DE60237425D1 (de) * 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
DE10238724A1 (de) * 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE102004004142A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
WO2004099211A1 (de) * 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
WO2005041972A1 (en) * 2003-10-31 2005-05-12 Pfizer Products Inc. Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
DE602005020611D1 (de) * 2004-04-28 2010-05-27 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
US8673964B2 (en) 2004-05-20 2014-03-18 Diamedica Inc. Use of drug combinations for treating insulin resistance
CN101198614B (zh) 2005-06-14 2011-07-06 Aska制药株式会社 噻吩并嘧啶衍生物
WO2007025103A2 (en) * 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Organic compounds for treating reduced dopamine receptor signalling activity
ES2581573T3 (es) * 2006-08-08 2016-09-06 Aska Pharmaceutical Co., Ltd. Derivado de quinazolina
WO2008028914A1 (en) 2006-09-07 2008-03-13 Nycomed Gmbh Combination treatment for diabetes mellitus
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
ES2599054T3 (es) 2006-12-13 2017-01-31 Aska Pharmaceutical Co., Ltd. Derivados de quinoxalina
JPWO2008072778A1 (ja) * 2006-12-13 2010-04-02 あすか製薬株式会社 尿路系疾患の処置剤
ITMI20070140A1 (it) * 2007-01-30 2008-07-31 Campagnolo Srl Dispositivo di interazione uomo-bicicletta
US20100144864A1 (en) * 2007-04-05 2010-06-10 Ironwood Pharmaceuticals, Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
EP2152712B1 (en) * 2007-05-11 2012-01-11 Pfizer Inc. Amino-heterocyclic compounds
PL2152663T3 (pl) 2007-06-04 2014-09-30 Ben Gurion Univ Of The Negev Research And Development Authority Związki triarylowe oraz kompozycje zawierające te związki
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
WO2009108383A2 (en) 2008-02-29 2009-09-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
PE20120505A1 (es) 2009-03-31 2012-05-09 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
ES2626006T3 (es) 2010-08-12 2017-07-21 Boehringer Ingelheim International Gmbh Derivados de 6-cicloalquil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como inhibidores de PDE9A
CA2810696C (en) 2010-09-07 2018-09-18 Astellas Pharma Inc. Pyrazoloquinoline compound
UY33616A (es) * 2010-09-20 2012-04-30 Envivo Pharmaceuticals Inc Compuestos con estructura de imidazotriazinona
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP3243385B1 (en) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
SG11201502728WA (en) 2011-10-10 2015-05-28 Lundbeck & Co As H Pde9i with imidazo pyrazinone backbone
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
WO2013181755A1 (en) 2012-06-04 2013-12-12 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN102786525B (zh) 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2015067538A (ja) * 2013-09-26 2015-04-13 株式会社アイエイアイ 血糖値降下剤
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CR20160207A (es) 2013-11-05 2016-08-10 Ben Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad
CA2981791A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
CN107810187B (zh) 2015-07-07 2020-09-15 H.隆德贝克有限公司 用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
UA125650C2 (uk) 2016-09-09 2022-05-11 Інсайт Корпорейшн Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AU2018230478A1 (en) 2017-03-09 2019-09-12 Diamedica Inc. Dosage forms of tissue kallikrein 1
ES2969895T3 (es) 2017-05-26 2024-05-23 Cardurion Pharmaceuticals Inc Métodos para obtener y usar inhibidores de PDE9
EP3634964B1 (en) 2017-06-08 2022-02-23 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde9 inhibitors
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
BR112020016927A2 (pt) 2018-02-20 2020-12-15 Incyte Corporation Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida e compostos relacionados como inibidores de hpk1 para tratar câncer
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
PT3801526T (pt) 2018-05-25 2024-03-26 Cardurion Pharmaceuticals Inc Formas mono-hidratas e cristalinas de 6-[(3s,4s)-4-metil- 1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran- 4-il-7h-imidazo[1,5-a]pirazin-8-ona
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
MX2022001562A (es) 2019-08-06 2022-04-26 Incyte Corp Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
US20240025904A1 (en) * 2020-10-27 2024-01-25 Cardurion Pharmaceuticals, Inc. Pde9 inhibitors for treating cardiac failure

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
DE19541264A1 (de) 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
EP0882718B1 (en) * 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
GB9722520D0 (en) * 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6444816B1 (en) * 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
US5922595A (en) * 1997-12-09 1999-07-13 Incyte Pharmaceuticals, Inc. Cyclic GMP phosphodiesterase
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
EP1146888A2 (en) 1998-10-15 2001-10-24 BioImage A/S Specific therapeutic interventions obtained by interference with redistribution and/or targetting
JP2004506009A (ja) * 2000-08-11 2004-02-26 ファイザー・インク インスリン抵抗性症候群の治療
JP2004527476A (ja) * 2001-02-02 2004-09-09 ファイザー・インク 真性糖尿病の処置
AUPR576801A0 (en) 2001-06-19 2001-07-12 University Of Tasmania Methods and pharmaceuticals for treating muscle insulin resistance and related conditions
IL161155A0 (en) * 2001-11-02 2004-08-31 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease

Also Published As

Publication number Publication date
CA2465632A1 (en) 2003-05-08
IL161155A0 (en) 2004-08-31
US6967204B2 (en) 2005-11-22
HUP0401998A2 (hu) 2005-01-28
KR20040053210A (ko) 2004-06-23
JP2005508978A (ja) 2005-04-07
CN1575191A (zh) 2005-02-02
BR0213817A (pt) 2004-10-19
US20040023989A1 (en) 2004-02-05
US20050070557A1 (en) 2005-03-31
WO2003037432A1 (en) 2003-05-08
PL370599A1 (en) 2005-05-30
EP1444009A1 (en) 2004-08-11
ZA200402173B (en) 2005-03-18

Similar Documents

Publication Publication Date Title
MXPA04004170A (es) Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
DE60116256D1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
IL158559A0 (en) Acne treatment
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
HUP0300725A2 (hu) Az inzulinrezisztencia-szindróma kezelése CGMP PDE5 inhibitorokkal
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
DE60115433D1 (de) Verfahren zur behandlung von chronischen geschwüren
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
BR0317095A (pt) Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease
WO2002064160A8 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
DK1441708T3 (da) Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
WO2005055956A3 (en) Method for improving insulin sensitivity by administering an inhibitor of antitrypsin
PT980253E (pt) Somatostatina e agonistas de somatostatina para tratar a insensibilidade a insulina e a sindrome x
ATE249235T1 (de) Anwendung der hemoproteine in der therapie
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
AR034375A1 (es) Combinacion de un inhibidor de ptpasa y un agente de sulfonilurea